Biopharmaceutical developer uniQure N.V. submitted a Form 8-K filing to the U.S. Securities and Exchange Commission confirming that the Food and Drug Administration accepted its Biologics License Application for ifezuntirgene inilparvovec, designated AMT-130. The investigational gene therapy is seeking accelerated approval as a disease-modifying treatment for Huntington's disease. The FDA granted the submission Priority Review designation and established a Prescription Drug User Fee Act target action date of May 1, 2027, accelerating regulatory evaluation timelines.
AMT-130 targets mutant huntingtin in Huntington's disease
Investigational Therapy Targets Underlying Genetic Pathology of Rare Neurodegenerative Disorder
Huntington's disease is an inherited, autosomal dominant neurodegenerative condition caused by an abnormal cytosine-adenine-guanine trinucleotide expansion within the huntingtin gene. The genetic alteration produces misfolded mutant huntingtin protein aggregates that progressively destroy neurons within the striatum and cerebral cortex.
Approximately 75,000 individuals across North America and Europe live with the progressive genetic disorder. No approved therapeutics currently exist that delay motor decline or halt disease progression, with diagnosed individuals typically experiencing total functional disability within two decades of symptom onset.
AMT-130 utilizes a recombinant adeno-associated virus serotype 5 vector to deliver microRNA designed to silence mutant huntingtin transcripts. Administered as a single-dose treatment via MRI-guided stereotactic neurosurgery directly into the caudate and putamen, the therapy inhibits toxic protein production directly within vulnerable brain structures.
Confirmatory trial to enroll 200 participants at 2:1 ratio
Three-Year Clinical Outcomes Demonstrate 75% Reduction in Disease Progression
Regulatory Alignment Establishes Framework for Phase 3 Confirmatory Protocol
To fulfill statutory criteria for accelerated market authorization, uniQure reached formal alignment with FDA review divisions regarding the parameters of a post-approval confirmatory trial. The trial design balances rigorous evidentiary criteria with ethical considerations regarding neurosurgical interventions.
The planned confirmatory investigation will enroll approximately 200 study participants randomized on a 2:1 ratio to receive AMT-130 alongside standard care or standard care alone. The protocol designates change in Total Functional Capacity at 36 months post-intervention as the primary efficacy endpoint.
FDA advisory committee and 20 neurosurgical centers prep
The regulatory consensus permits the use of concurrent standard care controls rather than invasive sham neurosurgical procedures. Screening procedures across United States clinical trial sites are scheduled to commence before the conclusion of 2026, ensuring that enrollment proceeds swiftly toward target milestones.
Advisory Committee Convening and Commercial Delivery Network Preparation
The FDA signaled plans to convene an independent advisory committee panel to examine the natural history comparative methodology and safety profile prior to issuing a final determination. The investigational candidate holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Fast Track designations.
Because the treatment requires precise intracranial stereotactic administration, uniQure is collaborating with more than 20 specialized academic neurosurgical centers across the United States to standardize operating room protocols.
UK MHRA parallel review for first Huntington's gene therapy
A parallel regulatory review is progressing before the United Kingdom Medicines and Healthcare products Regulatory Agency. If authorized by the May 2027 deadline, AMT-130 will represent the first approved gene therapy targeting Huntington's disease, establishing a historic therapeutic precedent for hereditary neurodegenerative disorders. Patient advocacy groups and clinical investigators across the international neurology community have welcomed the priority designation as an encouraging milestone for families navigating this devastating condition.
